Skip to main content

Table 1 Baseline characteristics of the study population

From: Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Clinical variable

Sorafenib, n (%)

Sunitinib, n (%)

P

Age (years)

<65

373 (77.2)

309 (85.4)

0.004

≥65

110 (22.8)

53 (14.6)

 

Gender

Male

353 (73.1)

276 (76.2)

0.302

Female

130 (26.9)

86 (23.8)

 

Pathology

Clear cell type

408 (84.5)

331 (91.4)

0.002

Non-clear cell type

75 (15.5)

31 (8.6)

 

ECOG

0

230 (47.6)

238 (65.7)

<0.001

1

188 (38.9)

94 (26.0)

 

2

58 (12.0)

29 (8.0)

 

3

7 (1.4)

1 (0.3)

 

Previous nephrectomy

Yes

376 (77.8)

298 (82.3)

0.120

No

107 (22.2)

64 (17.7)

 

MSKCC

Low risk

173 (35.8)

151 (41.7)

<0.001

Moderate risk

237 (49.1)

192 (53.0)

 

High risk

73 (15.1)

19 (5.2)

 

Heng’s criteria

Low risk

183 (37.9)

144 (39.8)

0.016

Moderate risk

227 (47.0)

187 (51.7)

 

High risk

73 (15.1)

31 (8.6)

 

Number of metastatic organs

1

207 (42.9)

174 (48.1)

0.129

2

182 (37.7)

109 (30.1)

 

3

75 (15.5)

66 (18.2)

 

4

19 (3.9)

13 (3.6)

 

Lung metastasis

No

174 (36.0)

106 (29.3)

0.046

Yes

309 (64.0)

256 (70.7)

 

Simple lung metastasis

No

380 (78.7)

251 (69.3)

0.002

Yes

103 (21.3)

111 (30.7)

 

Bone metastasis

No

319 (66.0)

254 (70.2)

0.207

Yes

164 (34.0)

108 (29.8)

 

Simple bone metastasis

No

445 (92.1)

341 (94.2)

0.276

Yes

38 (7.9)

21 (5.8)

 

Liver metastasis

No

421 (87.2)

335 (92.5)

0.013

Yes

62 (12.8)

27 (7.5)

 

Lymph node metastasis

No

323 (66.9)

248 (68.5)

0.656

Yes

260 (33.1)

114 (31.5)

 

RECIST response

CR

5 (1.0)

4 (1.1)

 

PR

77 (15.9)

72 (19.9)

 

SD

346 (71.6)

244 (67.4)

 

PD

55 (11.4)

42 (11.6)

0.110

Second line treatment

Yes

132 (27.3)

81 (22.4)

 

No

351 (72.7)

281 (77.6)

 
  1. ECOG eastern cooperative oncology group, MSKCC memorial sloan-kettering cancer centre, OS overall survival, PFS progression-free survival